|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
RU2003129528A
(ru)
*
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
EP1383785B1
(en)
*
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
DK1454138T3
(da)
*
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
ES2305886T3
(es)
*
|
2003-12-30 |
2008-11-01 |
Merck Patent Gmbh |
Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
|
|
RU2370276C2
(ru)
*
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
WO2009023184A2
(en)
*
|
2007-08-10 |
2009-02-19 |
Protelix, Inc. |
Universal fibronectin type iii binding-domain libraries
|
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
|
US8680019B2
(en)
*
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
SG175233A1
(en)
*
|
2009-04-22 |
2011-11-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
CU23734A1
(es)
*
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
KR20130118941A
(ko)
*
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
|
SG192673A1
(en)
*
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2723380B1
(en)
*
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
MY175687A
(en)
*
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
CA3191031A1
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
PT3172227T
(pt)
*
|
2014-07-21 |
2019-12-06 |
Delinia Inc |
Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
|
|
WO2016025647A1
(en)
*
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
US11371066B2
(en)
|
2015-07-13 |
2022-06-28 |
Modular Genetics, Inc. |
Generation of acyl alcohols
|
|
PT3328894T
(pt)
|
2015-08-06 |
2019-02-13 |
Agency Science Tech & Res |
Anticorpos de cadeia comum gama/il2rbeta
|
|
CN117659160A
(zh)
|
2015-09-11 |
2024-03-08 |
小利兰·斯坦福大学托管委员会 |
生物相关正交细胞因子/受体对
|
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
|
JPWO2018199318A1
(ja)
*
|
2017-04-28 |
2020-03-12 |
国立大学法人高知大学 |
抗ｇｐｃ−１抗体
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
EP3746103A4
(en)
|
2017-12-06 |
2022-03-30 |
The Board of Trustees of the Leland Stanford Junior University |
PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10752691B2
(en)
|
2018-03-13 |
2020-08-25 |
Tusk Therapeutics Ltd. |
Anti-CD25 antibody agents
|
|
KR102721494B1
(ko)
*
|
2018-04-17 |
2024-10-24 |
국립암센터 |
고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US11492384B2
(en)
*
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
CN111944036B
(zh)
*
|
2019-05-14 |
2024-09-06 |
上海盖浦生物科技有限公司 |
一种增殖免疫细胞的突变体蛋白
|
|
IL288210B2
(en)
|
2019-05-20 |
2026-03-01 |
Cytune Pharma |
Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
US20220372098A1
(en)
*
|
2019-06-26 |
2022-11-24 |
The Johns Hopkins University |
Methods and materials for targeted expansion of immune effector cells
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
KR20220044534A
(ko)
*
|
2019-08-13 |
2022-04-08 |
엘피스 바이오파마슈티컬즈 |
조작된 인터류킨-2 수용체 베타 효능제
|
|
CN121517534A
(zh)
|
2019-12-13 |
2026-02-13 |
辛德凯因股份有限公司 |
Il-2直向同源物及其使用方法
|
|
IL293471A
(en)
*
|
2019-12-17 |
2022-08-01 |
Amgen Inc |
Dual interleukin-2 / tnf receptor agonist for use in medicine
|
|
CN114437198A
(zh)
|
2019-12-17 |
2022-05-06 |
北京志道生物科技有限公司 |
白介素-2衍生物
|
|
WO2021122866A1
(en)
*
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
PE20231648A1
(es)
|
2020-04-22 |
2023-10-17 |
Merck Sharp And Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
|
|
EP4232068A1
(en)
|
2020-10-26 |
2023-08-30 |
Cytune Pharma |
IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
|
|
WO2022090203A1
(en)
|
2020-10-26 |
2022-05-05 |
Cytune Pharma |
IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
US20240067727A1
(en)
*
|
2020-12-17 |
2024-02-29 |
Ose Immunotherapeutics |
Bifunctional anti-pd1/il-7 molecules
|
|
MX2023011964A
(es)
*
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
US20250051414A1
(en)
*
|
2021-06-30 |
2025-02-13 |
The Regents Of The University Of California |
Altering cytokine specificity through binding valency
|
|
KR20240043797A
(ko)
|
2021-08-13 |
2024-04-03 |
싸이튠 파마 |
암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
|
|
EP4405487A4
(en)
*
|
2021-09-26 |
2025-12-03 |
Wuxi Biologics Ireland Ltd |
IL-2 VARIANTS AND THEIR FUSING PROTEINS
|
|
AU2022364888A1
(en)
*
|
2021-10-14 |
2024-05-30 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
|
|
CN119451978A
(zh)
|
2022-07-01 |
2025-02-14 |
神经基因治疗公司 |
Neo-2/15变体及其用于优先刺激T调节细胞的用途
|
|
EP4694916A1
(en)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
|
|
WO2025264955A1
(en)
*
|
2024-06-21 |
2025-12-26 |
Tfc Therapeutics, Inc. |
Multispecific proteins and related methods
|